Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for neuromuscular block reversal in major abdominal surgery
2014-005156-26Phase 4Completed
- Sponsor
- Dr. Enrique Alday
- Start
- Jan 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in Postoperative respiratory impairment (PRI) and atelectasis (2 arms), sponsored by Dr. Enrique Alday. Primary endpoints: Change in forced vital capacity from baseline to 1 hour postoperatively and Change in forced vital capacity from baseline to 24 hours postoperatively. Started Jan 2015; status: completed.
02
Drugs
Sugammadex
03
Conditions
Postoperative respiratory impairment (PRI)atelectasis
Beyond the preview
Go deeper on 2014-005156-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005156-26.